One of the first things people learn when they look for medical help with methamphetamine use disorder is that there is no FDA-approved medication for it — a frustrating gap that has led many people to conclude that medical treatment is simply not an option.
That conclusion is wrong. The absence of FDA approval reflects regulatory and research pipeline realities, not a lack of pharmacological options. Several medications have meaningful evidence behind them, and others are in active Phase II and Phase III trials with promising early results.
TL;DR: There is no FDA-approved medication specifically for methamphetamine use disorder (MUD). However, the bupropion/naltrexone combination was found in the 2021 ADAPT-2 trial to significantly reduce meth use in people with moderate-to-severe MUD. Bupropion alone, mirtazapine, and N-acetylcysteine also have supporting evidence. None of these medications require a specialty addiction provider — any primary care provider or psychiatrist can prescribe them. The most important step is being honest with a provider about meth use history.
Why There Is No FDA-Approved Medication for Meth
This gap has a specific history worth understanding.
For opioid use disorder, FDA approval of methadone, buprenorphine, and naltrexone followed decades of research, strong pharmaceutical industry interest (buprenorphine had commercial potential), and clear regulatory pathways. The mechanism — blocking or substituting at opioid receptors — was relatively tractable.
Methamphetamine use disorder operates through dopamine, norepinephrine, and serotonin pathways simultaneously, making a single-receptor-target approach less effective. The pharmaceutical industry has been slower to invest in this space. NIDA's Clinical Trials Network has carried much of the research burden, with recent results producing genuinely promising findings.
The absence of FDA approval does not mean medications don't work. It means the regulatory process has not yet completed for this specific indication.
The Best-Supported Option: Bupropion + Naltrexone
The most significant recent finding in meth pharmacotherapy comes from the ADAPT-2 trial, published in the New England Journal of Medicine in January 2021 by Trivedi MH and colleagues.
ADAPT-2 was a randomized, double-blind, placebo-controlled trial funded by NIDA that tested a combination of extended-release bupropion (450mg/day) and injectable naltrexone (380mg monthly) in 403 adults with moderate-to-severe methamphetamine use disorder.
Key finding: Participants receiving the bupropion/naltrexone combination were significantly more likely to have three or more weeks of confirmed meth abstinence during the 12-week trial — 13.6% in the active treatment group versus 2.5% in the placebo group. That is a clinically meaningful difference.
Why this combination?
-
Bupropion (Wellbutrin) is a dopamine and norepinephrine reuptake inhibitor. It acts on exactly the neurotransmitter systems that methamphetamine depletes, reducing the contrast between "using" and "not using" brain states while also addressing the depressive component of withdrawal. It is widely prescribed for depression and smoking cessation.
-
Naltrexone (Vivitrol as injectable, Revia as oral) is best known as an opioid antagonist, but it also modulates dopamine release in the mesolimbic system. By reducing dopamine spikes from drug use, it attenuates the rewarding properties of methamphetamine.
Neither medication is a substitute for meth — they work by normalizing brain chemistry, not by replicating drug effects.
Mirtazapine
Mirtazapine (Remeron) is a noradrenergic and specific serotonergic antidepressant with a distinct mechanism from SSRIs. It enhances both norepinephrine and serotonin signaling by blocking α2 receptors and 5-HT2/5-HT3 receptors.
The key evidence: Colfax GN and colleagues' 2011 placebo-controlled trial in methamphetamine-using men who have sex with men found that mirtazapine significantly reduced methamphetamine use compared to placebo over 12 weeks. The trial population was specifically chosen because this group had not responded well to other behavioral interventions.
Mirtazapine's sedating properties also make it useful for the insomnia that characterizes early meth withdrawal, and its weight-promoting effects can help with the nutritional deficits common in people stopping meth use.
It is not a first-line treatment for everyone — its side effect profile (sedation, weight gain) is dose-dependent — but it represents a meaningful option, particularly for people with prominent insomnia or significant weight loss.
Other Options With Evidence
N-acetylcysteine (NAC) modulates glutamate signaling in the corticostriatal pathways associated with craving and compulsive use behavior. Several pilot trials have shown reduced craving and compulsive picking behavior (which often accompanies meth use — see our article on meth skin damage). NAC is available over the counter and is commonly used at 600–2400mg/day; it has a favorable safety profile.
Modafinil (Provigil) is a wake-promoting agent sometimes used to manage the hypersomnia and fatigue of meth withdrawal. Evidence for reducing meth use itself is mixed, but it has utility as a supportive medication during the acute withdrawal period.
Ibudilast is a phosphodiesterase (PDE) inhibitor that reduces neuroinflammation — one of the mechanisms of meth neurotoxicity. The Phase II NIDA trial published by Trivedi and colleagues in 2017 showed positive signals for reducing meth craving. Phase III work is ongoing.
What About Contingency Management?
Contingency management (CM) deserves mention alongside pharmacotherapy because it has the strongest evidence base of any intervention for methamphetamine use disorder — often stronger than medication alone.
CM uses small, immediate incentives (vouchers, prize draws, cash) to reinforce confirmed abstinence. The mechanism is behavioral: it substitutes external dopamine-relevant rewards (winning something) for the dopaminergic hit of meth use during the period when the brain's natural reward system is still impaired.
The combination of CM and pharmacotherapy appears more effective than either alone. Several states now have CM programs available through their behavioral health infrastructure; NIDA maintains information on current availability.
How to Have This Conversation With a Provider
The most common barrier to accessing pharmacotherapy for meth use disorder is not medication availability — it is disclosure. Many people avoid being honest with their primary care provider about meth use out of fear of judgment, legal consequences, or effects on custody arrangements.
What matters to know:
- Substance use treatment records are protected under 42 CFR Part 2, providing confidentiality protections beyond standard HIPAA
- Primary care providers and psychiatrists can prescribe all of the medications discussed here; you do not need a specialist
- Providers who work in primary care or addiction medicine have heard this before; non-disclosure prevents appropriate care
You do not need to wait for a specialty addiction clinic. A conversation that starts with "I've been using methamphetamine and I want to stop — what medications might help?" can happen with any prescribing provider.
Find treatment including medication-prescribing providers: findtreatment.gov
The Realistic Picture
Medication for meth use disorder works best as part of a broader approach — behavioral support, structure, and the social infrastructure of recovery alongside pharmacological assistance. No medication alone produces lasting abstinence without behavioral change.
The 13.6% three-week abstinence rate in ADAPT-2 is more impressive than it sounds: the participants were people with moderate-to-severe use disorder who had not responded to other treatments. For people earlier in their disorder or with stronger behavioral support, outcomes are likely better.
The important takeaway: medication is an option. The absence of FDA approval has created a false impression that there is nothing medicine can offer. That is not accurate.
Support resources:
- SAMHSA National Helpline: 1-800-662-4357 (free, confidential, 24/7)
- Find treatment: findtreatment.gov
- 988 Suicide and Crisis Lifeline: call or text 988
Coach Aria is a private, 12-week digital coaching program for people recovering from stimulant addiction — providing the behavioral structure that works alongside any clinical treatment approach.